Feature | November 15, 2006| Ryan Hiett

Heart Central

When a “top 5” hospital and leading heart-assist

The AB5000 Circulatory Support Device from Abiomed Inc.

The AB5000 Circulatory Support Device from Abiomed Inc.

The AB5000 Circulatory Support Device from Abiomed Inc.

If its cancer care, emergency medicine, pediatric and maternal-fetal medicine specialties keep Robert Wood Johnson University Hospital (RWJUH) in New Brunswick at the forefront of nationally recognized hospitals, its heart center is what keeps it pumping.
The Heart Center of New Jersey, a 225-bed hospital-within-a-hospital, has excelled in providing primary angioplasty to heart attack patients, according to the U.S. Department of Health and Human Services’ Hospital Compare Web site, and was ranked in the state’s top five hospitals for heart attack care by the New Jersey Department of Health and Senior Services.
The center includes one of the busiest cardiac cath labs in the region. The Dr. Norman Reitman Cardiac Catheterization Laboratories is made up of seven labs, including two for cardiac electrophysiology. The suite handles more than 12,000 procedures each year.
In addition to diagnostic cath and coronary interventional procedures, cardiologists there are also performing peripheral vascular interventions in the labs.
The center houses RWJUH's Advanced Heart Failure and Transplant Cardiology Program, which offers heart treatments that include specialized medical, device and surgical therapy. The program offers care for patients with end-stage heart failure and has shorter waiting times for heart transplantation than most large metropolitan areas.
And now that its cardiac program has made it an Abiomed Inc. (Danvers, MA) “Center of Excellence,” RWJUH’s heart center is getting stronger every day.
A “Truly Rewarding” VAD
The “Center of Excellence” designation means the hospital is helping set standards for physician training on Abiomed’s ventricular assist devices (VADs), which provide temporary circulatory support for patients in acute heart failure. They also share best practices related to VAD implantation and patient care.
RWJUH’s chief of cardiac surgery Mark Anderson, M.D., led a national study on the use of Abiomed’s VADs titled “Mechanical Circulatory Support Improves Recovery Outcomes in Profound Cardiogenic Shock Post Acute Myocardial Infarction.”
The study found patients who suffered a heart attack followed by cardiogenic shock could recover the natural function of their heart when given Abiomed’s AB5000 circulatory support for an average of 31 days.
Of the patients who were able to survive the traumatic coronary event, 67 percent were able to recover. Dr. Anderson calls the results “truly rewarding.”
“I have found that by utilizing the AB5000, we are able to recover our patients’ hearts and send them home without a transplant, which can be costly and expose these patients to a variety of other problems,” he said.
By providing circulatory support, Dr. Anderson says an injured heart has time to rest. “If given enough time to rest, the cells of the heart can repair themselves,” he said.
And now the center is one of the few hospitals in the country with a fully implantable artificial heart coming its way — RWJUH was chosen in September to offer Abiomed’s newly FDA-approved AbioCor.
Dr. Anderson says 20,000 to 30,000 patients a year could benefit from the technology, according to an article from USA Today.
“There are a million acute heart attacks a year in this country,” he said. “About 70,000 are complicated by shock, and from 30 to 50 percent don’t respond to conventional therapy.”
A two-year study led by Dr. Anderson and financed by Abiomed tracked every patient who received treatment from the device to give their hearts a break after massive heart attacks. The 50-patient study was the first evidence that the device saves lives.
“We’ve basically doubled survival,” Dr. Anderson said. “Not only was survival improved, but nearly 70 percent recovered their native cardiac function. It’s one thing to have a patient survive and go home in heart failure. It’s another to go home with good heart function. The pumps minimize injury to the heart.”
Transmyocardial Revascularization
The center is also one of a few hospitals in the world that offer a new laser procedure to treat inoperable coronary artery disease (CAD).
During transmyocardial revascularization (TMR), a surgeon makes an incision on the left breast to expose the heart. Using a laser, the surgeon drills a series of holes from outside of the heart into the heart’s pumping chamber. From 20 to 40mm laser channels are placed during the procedure.
Bleeding from the laser channels on the outside of the heart stops after a few minutes of pressure from the surgeon’s finger.
In some patients TMR is combined with bypass surgery. In those cases, an incision through the breastbone is used.

Related Content

Freedom Driver, SynCardia, recall, Total Artificial Heart, TAH-t, part failure

Freedom Driver attached to Total Artificial Heart. Image courtesy of SynCardia.

News | Ventricular Assist Devices (VAD)| September 18, 2015
SynCardia Systems initiated a Class I recall of the Freedom Driver Systems used with the company’s temporary Total...
Thoratec, HeartMate II LVAS, Urgent Device Correction Letter, Pocket System Controller, backup battery
News | Ventricular Assist Devices (VAD)| September 16, 2015
Thoratec Corp. issued a voluntary Urgent Medical Device Correction Letter to all hospitals who have patients supported...
Maquet, extracorporeal life support, ECLS, cardiogenic shock, bridge-to-life, PLS system

PLS system image courtesy of Maquet

News | ECMO Systems| September 08, 2015
In a new study reported in The Journal of Thoracic and Cardiovascular Surgery, researchers found a dramatic difference...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
Mayo Clinic, LVAD, study, heart failure, restrictive cardiomyopathy, RCM

Thoratec HeartMate II image courtesy of Thoratec

News | Ventricular Assist Devices (VAD)| August 07, 2015
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating...
FDA, warning, LVADs, left ventricular assist devices, Thoratec, HeartMate II, HeartWare, HVAD
News | Ventricular Assist Devices (VAD)| August 06, 2015
The U.S. Food and Drug Administration (FDA) is alerting healthcare providers, patients and caregivers about serious...
HeartWare, ventricular assist device, HeartWare VAD, recall, update
News | Ventricular Assist Devices (VAD)| August 05, 2015
HeartWare expanded the Class I recall of its ventricular assist device in mid-June due to concerns over damaged or...
LVADs, heart failure patients, echocardiography, ASE, recommendations, guideline
News | Cardiovascular Ultrasound| August 04, 2015
Over the past several years, advanced heart failure patients who have not responded to medical therapy have been given...
HeartMate PHP, Thoratec, St. Jude medical

The HeartMate PHP (percutaneous heart pump) is the latest acute hemodynamic support technology released by Thoratec, which recently received CE mark in Europe. The PHP is currently in U.S.clinical trials.

Feature | Ventricular Assist Devices (VAD)| July 22, 2015
St. Jude Medical and Thoratec announced that the boards of directors of both companies have unanimously approved a...
ACC, health policy statement, heart team, cardiovascular health
Feature | Cardiovascular Surgery| July 17, 2015
Building teams that include advanced practice providers can help cardiovascular practices meet the challenges of modern...
Overlay Init